American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology have released a new guideline for germline testing in patients with breast cancer. This recent guideline addresses the framework on how to approach germline testing in breast cancer and makes recommendations for who and which genes should be tested.
- BRCA 1/2 testing is now recommended for anyone diagnosed with invasive breast cancer before the age of 65
- Those with recurrent breast cancer, suitable for PARP inhibitor therapy, should consider BRCA 1/2 testing, regardless of their family history
- Testing for moderate penetrance breast cancer genes currently offers no benefits for treatment of the index breast cancer but may inform risks of second primary cancer or family risk assessment, and thus may be offered to appropriate patients who are undergoing BRCA1/2 testing
Learn more: https://ascopubs.org/doi/10.1200/JCO.23.02225